AB-Biotics was founded in 2004 as a spin-off of the Autonomous University of Barcelona (UAB) launched by Miquel Àngel Bonachera and Sergi Audivert, currently executive directors and members of the company’s Board of Directors.
Now it is a leading biotechnology company, with an international vocation, and it divides its activities into these two main business areas (probiotics & precision medicine) based on research, development, intellectual protection and the distribution of their own exclusive biotechnological solutions through a Business to Business (B2B) model.
ActivityThe company's efforts focus on these two fields:
- Probiotics: license of propiotic and proprietary strains. These strains have specific mechanisms of action that are validated through clinical studies.
- Precision medicine: Through Neurofarmagen, a pharmacogenetic test that facilitates the choice of the most appropriate medication by the psychiatrist, improving therapeutic efficacy and minimizing adverse effects.